The Vanguard Group, Inc. recently announced the acquisition of new stake in Cyclo Therapeutics Inc (NASDAQ:CYTH). The institutional investor has increased its shareholding in the Healthcare company by 9.68% to 0.28 million shares with purchase of 24888.0 shares. This fresh investment now brings its stake to 1.24% valued currently at $0.45 million. In addition, Geode Capital Management LLC raised its holdings by 119.0 to 0.1 million shares. And SSgA Funds Management, Inc. has lifted its position by 13.78% or 3900.0 shares – to 32200.0 shares.
With over 0.49 million Cyclo Therapeutics Inc (CYTH) shares trading Friday and a closing price of $1.86 on the day, the dollar volume was approximately $0.9 million. The shares have shown a positive half year performance of 27.40% and its price on 01/12/24 gained nearly 29.17%. Currently, there are 22.77M common shares owned by the public and among those 10.67M shares have been available to trade.
Insiders at the company have transacted a total of 22 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 7,651,316 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Cyclo Therapeutics Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.18 million shares of the company’s stock, all valued at over $0.28 million. Vanguard Extended Market Index Fu bought 4316.0 shares to see its total holdings expand to 0.11 million shares valued at over $0.17 million and representing 0.48% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.33% of the shares outstanding.
Shares of Cyclo Therapeutics Inc (NASDAQ: CYTH) opened at $1.42, down -$0.02 from a prior closing price of $1.44. However, the script later moved the day high at 1.8800, up 29.17%. The company’s stock has a 5-day price change of 17.72% and 73.83% over the past three months. CYTH shares are trading 16.98% year to date (YTD), with the 12-month market performance down to -1.59% lower. It has a 12-month low price of $0.67 and touched a high of $2.57 over the same period. CYTH has an average intraday trading volume of 87.80K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.36%, 32.39%, and 36.67% respectively.
Institutional ownership of Cyclo Therapeutics Inc (NASDAQ: CYTH) shares accounts for 2.11% of the company’s 22.77M shares outstanding. Mutual fund holders own 1.68%, while other institutional holders and individual stakeholders account for 49.18% and 0.43% respectively.
It has a market capitalization of $42.35M and a beta (3y monthly) value of -0.13. The earnings-per-share (ttm) stands at -$1.67. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.23% over the week and 13.44% over the month.
Analysts forecast that Cyclo Therapeutics Inc (CYTH) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.5 a year ago.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Cyclo Therapeutics Inc (CYTH) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
